Human GABA B (c-aminobutyric acid class B) receptor is a G-protein-coupled receptor central to inhibitory neurotransmission in the brain. It functions as an obligatory heterodimer of the subunits GBR1 and GBR2. Here we present the crystal structures of a heterodimeric complex between the extracellular domains of GBR1 and GBR2 in the apo, agonist-bound and antagonist-bound forms. The apo and antagonist-bound structures represent the resting state of the receptor; the agonist-bound complex corresponds to the active state. Both subunits adopt an open conformation at rest, and only GBR1 closes on agonist-induced receptor activation. The agonists and antagonists are anchored in the interdomain crevice of GBR1 by an overlapping set of residues. An antagonist confines GBR1 to the open conformation of the inactive state, whereas an agonist induces its domain closure for activation. Our data reveal a unique activation mechanism for GABA B receptor that involves the formation of a novel heterodimer interface between subunits.
Human GABA B (c-aminobutyric acid class B) receptor is a G-protein-coupled receptor central to inhibitory neurotransmission in the brain. It functions as an obligatory heterodimer of the subunits GBR1 and GBR2. Here we present the crystal structures of a heterodimeric complex between the extracellular domains of GBR1 and GBR2 in the apo, agonist-bound and antagonist-bound forms. The apo and antagonist-bound structures represent the resting state of the receptor; the agonist-bound complex corresponds to the active state. Both subunits adopt an open conformation at rest, and only GBR1 closes on agonist-induced receptor activation. The agonists and antagonists are anchored in the interdomain crevice of GBR1 by an overlapping set of residues. An antagonist confines GBR1 to the open conformation of the inactive state, whereas an agonist induces its domain closure for activation. Our data reveal a unique activation mechanism for GABA B receptor that involves the formation of a novel heterodimer interface between subunits.
GABA is the predominant inhibitory neurotransmitter in the central nervous system. Metabotropic GABA B receptor is a G-protein-coupled receptor that mediates slow and prolonged synaptic inhibition through G i or G o protein 1, 2 . Presynaptic GABA B receptor suppresses neurotransmitter release, and postsynaptic GABA B receptor causes hyperpolarization of neurons 1, 2 . Malfunction of GABA B receptor can lead to various neurological disorders, including spasticity and epilepsy [1] [2] [3] . Baclofen, a selective GABA B agonist, is used clinically to treat muscle spasticity associated with multiple sclerosis, cerebral palsy and spinal cord injury [1] [2] [3] .
GABA B receptor belongs to the distinct class-C family of G-proteincoupled receptors 4 . Ligand binding to these receptors takes place within a large extracellular Venus flytrap (VFT) module that has sequence homology to bacterial periplasmic amino-acid-binding proteins 4 . Unlike metabotropic glutamate receptors (mGluRs) and extracellular-calciumsensing receptor, which function as disulphide-tethered homodimers [5] [6] [7] [8] , GABA B and taste receptors act as heterodimers [9] [10] [11] [12] [13] [14] [15] [16] . GABA B receptor functions as a heterodimeric assembly of the subunits GBR1 and GBR2 (refs 9-12, 14) . GBR2 facilitates cell surface expression of GBR1 by masking an endoplasmic reticulum retention signal of GBR1 (refs 17, 18) . GBR1 is responsible for ligand recognition through its extracellular domain 19, 20 . Although GBR2 does not bind any known GABA B ligand [9] [10] [11] 21 , its ectodomain directly interacts with the GBR1 ectodomain to enhance agonist affinity 10, 11, [22] [23] [24] [25] [26] and is required for receptor activation 22, 25, 27 . Finally, the transmembrane domain of GBR2 is responsible for G-protein coupling 22, 25, [28] [29] [30] [31] [32] .
Most of the current knowledge about the structures of class-C G-protein-coupled receptors derives from homodimeric mGluRs. The ectodomain structures of three mGluR subtypes have been determined with and without ligand [33] [34] [35] . Here we assembled a stable heterodimeric complex of the human GBR1 and GBR2 ectodomains, and determined its crystal structure in the absence of ligand and in the presence of various agonists and antagonists. Together with our mutational data, these structures provide insights into the molecular mechanisms of receptor heterodimerization, ligand recognition and receptor activation.
Structures of GABA B heterodimer
The extracellular VFT module of human GBR1b (GBR1b VFT ) and GBR2 (GBR2 VFT ) were co-secreted as a heterodimeric complex from insect cells ( Supplementary Fig. 1 ). The GBR1b VFT :GBR2 VFT heterodimer binds various agonists and antagonists with the same rank order of affinities as the full-length receptor, indicating that it is physiologically relevant 26 .
We determined the crystal structure of the GBR1b VFT :GBR2 VFT complex in the apo form, when bound to six different antagonists (CGP54626 ANT , CGP46381 ANT , CGP35348 ANT , SCH50911 ANT , (S)-2-OH-saclofen ANT and (R)-phaclofen ANT ) and when bound to two different agonists (endogenous ligand GABA and clinical drug (R)baclofen AGO ) ( Supplementary Table 1 ). Each structure consists of a noncovalent heterodimer of GBR1b VFT and GBR2 VFT , in which the protomers are bound to each other such that they are side by side and facing opposite directions ( Fig. 1 and Supplementary Fig. 2 ). All of the agonists and antagonists bind in the crevice between the LB1 and LB2 domains of GBR1b VFT .
GBR1b VFT and GBR2 VFT have similar overall structures, in agreement with their sequence homology (33% identity) ( Supplementary  Fig. 3 ). Both subunits have a bi-lobed architecture related to that found in mGluRs [33] [34] [35] , natriuretic peptide receptors 36, 37 , ionotropic glutamate receptors [38] [39] [40] and periplasmic amino-acid-binding proteins 41 . However, the extracellular domains of GBR1b and GBR2 lack the cysteine-rich region found at the carboxy-terminal end of mGluR ectodomains. Each GABA B subunit contains two distinct domains, LB1 and LB2. The individual LB1 and LB2 domains of the two subunits are highly correlated with each other.
Despite similarities, the GBR1b VFT and GBR2 VFT structures have different interdomain arrangements, consistent with their disparate ligand-binding characteristics ( Fig. 2a, b ). The ligand-binding subunit, GBR1b VFT , can oscillate between open and closed conformations, in which the more compact closed conformation is associated with agonist binding. In contrast, the non-ligand-binding subunit, GBR2 VFT , has nearly identical conformations with and without dimer partner GBR1 VFT .
In the crystal structure of apo-GBR1b VFT :GBR2 VFT , both subunits adopt an open conformation when compared with the known structures of mGluRs [33] [34] [35] ( Supplementary Fig. 4 ). All six antagonist-bound structures closely resemble that of the apo complex, both in the arrangement of the heterodimer and in the structures of the individual subunits ( Supplementary Fig. 4 ). The ligand-binding cleft of GBR1b VFT stays open with each bound antagonist. In addition, GBR2 VFT Agonist binding causes large conformational changes within the heterodimeric complex. First, both the agonists GABA and (R)-baclofen AGO induce domain closure of GBR1b VFT , as previously predicted 42 (Fig. 2a ). When the LB1 domains of apo and agonist-bound GBR1b VFT are superimposed, their LB2 domains can be related by a 29u rotation about a nearly horizontal interdomain axis. Because the rotational axis has a slight vertical offset, this transformation also brings the LB2 domain of GBR1b VFT into close contact with the LB2 domain of GBR2 VFT to form a large heterodimer interface unique to the active state.
Second, GBR2 VFT remains open in the agonist-bound state, consistent with our previous prediction that GBR2 VFT has a constitutively open conformation 26 . Nevertheless, the LB2 domain of GBR2 VFT undergoes a twist motion of 9u around a nearly vertical axis, and moves towards the LB2 domain of GBR1b VFT to form new heterodimeric contacts ( Fig. 2b) .
Finally, the substantial rearrangement of the LB2 domains from the apo to the agonist-bound state shortens the distance between the C termini of the two subunits from 45 to 32 Å (Fig. 2c, d and Supplementary   Fig. 5 ). This decrease in the separation between membrane-proximal LB2 domains may lead to changes in the relative orientation of the transmembrane domains. In summary, both agonist-bound GBR1b VFT : GBR2 VFT complexes adopt a closed-open structural arrangement, which corresponds to the active state of the receptor ( Supplementary Fig. 4 ).
Common subunit-subunit interactions
In both the resting and active states, GBR1b VFT and GBR2 VFT interact through their LB1 domains ( Supplementary Figs 6 and 7 ). In the apo 
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and antagonist-bound structures, the subunit association is exclusively facilitated by this LB1-LB1 contact. The heterodimer buries more than 1,400 Å 2 of solvent-accessible surface area and has exceptionally high interfacial shape correlation (Supplementary Table 2 ). The LB1-LB1 interaction is mediated by the B and C helices of both subunits (Fig. 3a) . The heterodimer interface can be divided into three regions (Fig. 3b ). Site I is located at the centre of the interface, and it is flanked, one on either side, by sites II and III.
Site I consists of a central hydrophobic patch surrounded by hydrogen bonds. The heterodimer contacts within this site are highly conserved in all of the GBR1b VFT :GBR2 VFT structures. In particular, it features three deeply buried tyrosine residues (Tyr 113 and Tyr 117 of GBR1b VFT and Tyr 118 of GBR2 VFT ) that are critical for heterodimer interaction and receptor activation 26 . These tyrosine residues participate in aromatic stacking interactions, and form interfacial hydrogen bonds. Together with the adjacent lysine and tryptophan residues, they are responsible for the majority of hydrophobic contacts at the LB1-LB1 heterodimer interface.
Interactions at site II are mostly hydrogen bonds, and include a universal salt bridge (GBR1b VFT -R141:GBR2 VFT -D109) as well as a conserved hydrogen bond (GBR1b VFT -E138:GBR2 VFT -N110). Site III consists predominantly of water-mediated contacts, and is the most variable part of the LB1-LB1 interface.
Agonist-induced heterodimer interface
Agonist binding induces the formation of an additional heterodimer interface between the LB2 domains of the GBR1b VFT and GBR2 VFT subunits ( Supplementary Fig. 7 ). This is consistent with our calorimetry measurements showing that GBR2 VFT has higher affinity for agonistbound than antagonist-bound GBR1b VFT (ref. 26 ). The LB2-LB2 interface buries more than 1,300 Å 2 of solvent-accessible surface area, has poor shape complementarity and is dominated by polar interactions (Supplementary Table 2 ).
The LB2-LB2 interaction is mediated by two strand-loop-helix motifs from each LB2 domain ( Fig. 3c ). Neighbouring strands f and g are part of the central b-sheet in LB2, and helices F and G flank the b-sheet. The heterodimer contacts consist primarily of hydrogen bonds, some of which are mediated by water molecules. The interface can be divided into three adjacent areas ( Fig. 3d ). Sites IV and V each features a large cluster of hydrogen bonds, and site VI mostly consists of isolated contacts. The GBR2 VFT residue Asn 213 is located at the intersection of sites IV and V, and it bridges the hydrogen-bond networks within these two regions. In addition, a minor LB2-LB1 contact involving helix D of GBR2 VFT is formed at the edge of site IV.
To confirm the importance of the LB2-LB2 heterodimer interface to receptor activation, we carried out alanine-scanning mutagenesis of the interfacial residues. We identified several polar residues from each subunit that are critical to agonist-dependent G i -protein activity (Supplementary Fig. 7) . These include the GBR1b VFT residues Thr 198, Glu 201 and Ser 225, and the GBR2 VFT residues Asp 204, Gln 206, Asn 213 and Ser 233. All of these residues are engaged in multiple interfacial hydrogen bonds at the LB2-LB2 interface. This reliance on hydrophilic interactions to form a distinct subunit interface in the active state allows the receptor to dissociate readily on returning to its resting state. Previous studies have also shown that introduction of a large N-linked glycan into the LB2 domain of either GABA B subunit inhibits agonistinduced receptor activation 43 .
Ligand recognition
All of the antagonists are derivatives of GABA, and have the general structure of a c-amino acid. The receptor-antagonist interactions are mediated largely by hydrogen bonds (Fig. 4a, b and Supplementary  Fig. 8 ). First, each antagonist is anchored at the crevice of GBR1b VFT by two sets of hydrogen bonds. The a-acid group at one end forms hydrogen bonds with the LB1 residues Ser 130 and Ser 153, and the c-amino group at the other end is hydrogen-bonded to His 170 and Glu 349. Second, Trp 65 makes van der Waals contacts with all of the antagonists. Third, the b-hydroxyl substituent of CGP54626 ANT and (S)-2-OH-saclofen ANT makes additional hydrogen bonds with the receptor that are specific to these antagonists. Finally, all of the antagonists except SCH50911 ANT and (R)-phaclofen ANT participate in watermediated interaction with Ser 131. These extensive contacts indicate that the LB1 domain is primarily responsible for anchoring antagonist.
In contrast, the interaction between the LB2 domain and bound antagonist is sparse and varies among the different antagonists (Supplementary Fig. 8 ). Only two antagonists, CGP54626 ANT and SCH50911 ANT , directly contact Trp 278 of LB2 through a large c-substituent. As a result of this additional LB2 interaction, both compounds have higher binding affinity to GABA B receptor than the other antagonists reported here 3 . This suggests that the LB2 domain has an auxiliary role in antagonist recognition, and enhances the potency of selective antagonists.
GABA B receptor recognizes both the agonists GABA and (R)baclofen AGO in essentially the same manner (Fig. 4c, d and Supplementary Fig. 9 ). (R)-baclofen AGO is a derivative of GABA, and contains a 
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chlorophenyl substituent at the b-position. Like the antagonists, each agonist is secured by two hydrogen-bond networks, one at each end of the molecule. Furthermore, a common set of LB1 residues is involved in binding the two ends of all of the agonists and antagonists. Unlike the antagonists, both agonists also directly contact two key residues of the LB2 domain, Tyr 250 and Trp 278. In addition, the two tryptophan residues Trp 65 and Trp 278 make extensive van der Waals contacts with both GABA and (R)-baclofen AGO . Therefore, both the LB1 and LB2 domains are required for agonist recognition. The binding sites of GABA and (R)-baclofen AGO differ in the sidechain conformation of the LB2 residue Trp 278 ( Supplementary Fig. 9 ). Relative to its orientation in the GABA-bound complex, the indole ring of Trp 278 is flipped by ,170u to accommodate the b-chlorophenyl substituent of (R)-baclofen AGO , which forms aromatic-ring-stacking interactions with both Tyr 250 and Trp 278. In contrast, GABA makes van der Waals contact with Trp 278 alone through its aliphatic backbone. The conformational adaptability of Trp 278 provides a mechanism by which the receptor recognizes structurally different ligands while maintaining ligand-binding specificity and affinity.
Agonist action versus antagonist action
The function of a GABA B agonist is to stabilize the closed conformation of GBR1b VFT , whereas that of an antagonist is to confine the GBR1b VFT subunit to the open configuration ( Supplementary Fig. 10 ). Agonist-bound GBR1b VFT has a closed cleft; the agonist is buried and inaccessible to the bulk solvent. In contrast, antagonist-bound GBR1b VFT has an open cleft, and the antagonist is solvent accessible.
The presence of a bulky substituent in each antagonist inhibits domain closure of GBR1b VFT . The highly potent antagonist CGP54626 ANT contains an a-cyclohexyl group and a c-dichlorophenyl group. The adverse interactions of these moieties with Tyr 250 and Trp 278 would be expected to prevent the LB1 and LB2 domains from approaching each other (Fig. 4e) . Similarly, each of the other antagonists CGP46381 ANT , CGP35348 ANT and SCH50911 ANT has a bulky substituent at either the a-position or the c-position to block GBR1b VFT domain closure (Supplementary Figs 8 and 9 ). Although the antagonists (S)-2-OH-saclofen ANT and (R)-phaclofen ANT are structurally analogous to the agonist (R)baclofen AGO , their a-acid motifs assume a tetrahedral coordination geometry that is incompatible with the active-state conformation of Tyr 250 (Fig. 4f) . Furthermore, the a-substituents push the b-chlorophenyl ring towards the c-amino end of each antagonist, thereby generating potential steric interactions with Ile 276 and Trp 278 to prevent GBR1b VFT domain closure.
All of the residues at the ligand-binding site are conserved within GBR1 sequences across different species ( Supplementary Fig. 11 ). Some of the ligand-binding residues, including Ser 130, Gly 151, Ser 153 and Glu 349 of GBR1b, have been implicated by previous studies 21, 26, [44] [45] [46] .
The LB1 residues are required for both agonist and antagonist recognition. We found that the Trp65Ala substitution caused substantial loss of ligand binding and receptor function (Fig. 4g, h) . The His170Ala mutation essentially abolished antagonist binding, and lowered the maximum agonist-induced [ 35 S]GTPcS binding to half that of wildtype level (Fig. 4g, h) . These data indicate that both Trp 65 and His 170 are indispensable for ligand recognition.
The LB2 residues are essential for agonist binding. First, the Trp278Ala mutant retained the ability to bind the antagonist [ 3 H]CGP54626 ANT , although with decreased potency (Fig. 4g ). This is consistent with the auxiliary role of Trp 278 in antagonist recognition. However, this mutation is detrimental to receptor activation, because it not only reduced the maximum GABA-dependent [ 35 S]GTPcS binding, but also increased the half-maximum effective concentration (EC 50 ) of GABA by more than 500-fold ( Fig. 4h) . Second, the Tyr250Ala mutation had no effect on antagonist binding, in agreement with our structural observations (Fig. 4g ). However, it decreased the agonist response, and increased the EC 50 of GABA by more than 100-fold (Fig. 4h) . These data indicate that both Tyr 250 and Trp 278 are critical to agonist recognition.
Implications for receptor activation
Structural comparison indicates that the concept of major intersubunit relocation that holds for the activation of mGluRs cannot be applied to GABA B receptor. The extracellular domains of these receptors share a common mode of dimerization through their LB1 domains (Supplementary Figs 12 and 13) . The resting and active configurations of mGluRs differ by a 70u rotation in dimer orientation [33] [34] [35] . Both closed-open and closedclosed conformations have been reported for activated mGluRs [33] [34] [35] , although full activation requires the closure of both protomers 47 . In contrast, the heterodimeric LB1-LB1 interface of GABA B receptor undergoes a minor 5u rotation in dimer orientation on agonist binding, and the receptor adopts only a closed-open active conformation.
ARTICLE RESEARCH
Our data indicate that activation of GABA B receptor involves the formation of a novel LB2-LB2 heterodimer interface. We carried out disulphide crosslinking studies 48 to determine the physiological relevance of the LB2-LB2 interaction in full-length receptor. On the basis of the active-state structure of GBR1b VFT :GBR2 VFT , we introduced cysteine mutations into a residue pair across the LB2-LB2 dimer interface (GBR1-Thr198Cys and GBR2-Gln206Cys), which had the proximity and geometry required for disulphide formation (Fig. 5a ). Western-blot analysis indicates that co-expression of wildtype GBR1b and GBR2 or the combination of a single cysteine mutant with its wild-type partner in mammalian cells produced monomeric protein bands in the presence of GABA under both reducing and nonreducing conditions (,95 kDa for GBR1b; ,115 kDa for GBR2) (Fig. 5b) . In contrast, co-expression of the cysteine mutant pair yielded a heterodimeric protein band (,210 kDa) under non-reducing conditions (Fig. 5b) . This band was recognized by both anti-Flag and anti-HA antibodies, which were used to detect differentially tagged GBR1b and GBR2 subunits. Furthermore, it was observed in the absence of ligand and in the presence of the agonist GABA. These observations indicate the spontaneous formation of a disulphide-tethered GBR1b:GBR2 heterodimer, and confirm that the LB2-LB2 interface observed in the active-state GBR1b VFT :GBR2 VFT structure is also present in free and agonist-bound native GABA B receptor.
To determine the functional effects of locking the LB2-LB2 interface, we measured agonist-dependent G i -protein activation of different combinations of wild-type and cysteine mutant receptors (Fig. 5c ). For the wild-type receptor and single cysteine mutants, application of GABA led to stimulation of [ 35 S]GTPcS binding both in the absence and presence of dithiothreitol (DTT). In contrast, the double cysteine mutant exhibited constitutive activity under non-reducing conditions, and addition of GABA did not further increase its functional activity (Fig. 5c ). This indicates that the intersubunit disulphide bond holds the receptor in a fully active form. Indeed, on reduction of the disulphide bond, the double cysteine mutant receptor lost its constitutive activity, but regained sensitivity to GABA to a level comparable to that of a single cysteine mutant (Fig. 5c ). Our data demonstrate that formation of the LB2-LB2 interface is both necessary and sufficient for GABA B receptor activation.
In the conformational equilibrium of GABA B receptor, an antagonist maintains the inactive conformation of the receptor, whereas an agonist stabilizes its active conformation ( Supplementary Fig. 14) . Agonist binding to GABA B receptor induces domain closure in the GBR1 subunit, an expansion of the heterodimer interaction to include a large LB2-LB2 interface, and a decrease in the separation between the membrane-proximal LB2 domains. Because receptor function is not affected by alterations in the peptide linker between the VFT and transmembrane domains of each subunit 27 , these changes would probably be directly relayed to the transmembrane domains. We expect that the transmembrane domains of the GABA B subunits exist as pre-formed heterodimers on the cell surface because both the extracellular and the intracellular components form stable heterodimers 12, 23, 24, 26, 49 . Therefore, agonist-induced conformational changes may lead to a rearrangement of the transmembrane-domain heterodimer for signal transduction across the membrane. This novel activation mechanism would be, as of yet, unique to inhibitory GABA B receptor.
METHODS SUMMARY
The extracellular VFT module of human GBR1b and GBR2 were co-secreted from baculovirus-infected insect cells, and purified by anti-Flag M2 antibody affinity chromatography followed by size-exclusion chromatography. Apo and antagonistbound GBR1b VFT :GBR2 VFT complexes were crystallized in the P2 1 space group. Agonist-bound complexes were crystallized in the P2 1 2 1 2 space group. All of the structures were solved by molecular replacement. Radioligand binding and agoniststimulated [ 35 S]GTPcS binding were measured using HEK293 cells co-transfected with complementary DNAs encoding full-length GBR1b and GBR2.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Protein expression and purification. The extracellular domains of human GBR1 and GBR2 were separately cloned into the pFBDM vector 50 for expression in baculovirus-infected insect cells. The GBR1 isoform GBR1b 19 was used in this study. The GBR1b VFT construct contained residues 48-459, with the signal peptide of baculovirus envelope surface glycoprotein gp67 attached at the N terminus and a Flag tag at the C terminus. The GBR2 VFT construct contained residues 1-466 and a C-terminal Flag tag, as previously described 26 . Sf9 insect cells were co-infected with recombinant GBR1b VFT and GBR2 VFT baculoviruses at 23 uC for 96 h. The GBR1b VFT :GBR2 VFT complex was purified from cell supernatant by anti-Flag antibody (M2) affinity chromatography followed by gel filtration chromatography (Superdex 200, GE Healthcare). The CGP54626 ANT -GBR1b VFT :GBR2 VFT complex was produced in the presence of 10 mM CGP54626 ANT throughout expression and 20 mM CGP54626 ANT during purification. The (R)-baclofen AGO -GBR1b VFT :GBR2 VFT complex was expressed and purified in the presence of 100 mM (R)-baclofen, and the GABA-GBR1b VFT : GBR2 VFT complex was produced in the presence of 100 mM GABA. Crystallization and data collection. Crystals of the apo-GBR1b VFT :GBR2 VFT complex were grown at 4 uC in 10% PEG 3350, 20% glycerol and 0.12 M Na acetate, pH 7.0. Crystals of various antagonist-bound GBR1b VFT :GBR2 VFT complexes were obtained under the same condition as the apo complex. Specifically, the CGP54626 ANTbound heterodimer was crystallized using protein that was purified in the presence of CGP54626 ANT . The apo-GBR1b VFT :GBR2 VFT complex was also co-crystallized with 10 mM of each of the following antagonists: CGP46381 ANT , CGP35348 ANT , SCH50911 ANT , (R,S)-2-OH-saclofen ANT and (R,S)-phaclofen ANT . All of the crystals were directly frozen from drops. Native data for the different complexes were collected at the 24ID-C and 24ID-E beamlines of the Advanced Photon Source. Diffraction data for the apo complex and the CGP46381 ANT -, CGP35348 ANT -, SCH50911 ANT -and GABA-bound complexes were integrated using XDS 51 and scaled with SCALA 52 . Data for the CGP54626 ANT -, (S)-2-OH-saclofen ANT -, (R)-phaclofen ANT -and (R)-baclofen AGObound complexes were integrated and scaled using HKL2000 53 . Structure determination. The structure of the apo-GBR1b VFT :GBR2 VFT complex was solved by molecular replacement. The position of GBR2 VFT was identified using the structure of free GBR2 VFT (PDB code 4F11; ref. 26 ) as the search model. The location of GBR1b VFT was found by using the individual LB1 and LB2 domains of GBR2 VFT as the search probes. A complete atomic model of the apo-GBR1b VFT :GBR2 VFT complex was developed through a succession of manual building and iterative refinement. The final model contained the GBR1b VFT residues 48-368 and 377-459, the GBR2 VFT residues 53-292, 300-379 and 385-466, and part of the Flag tag at the C termini of both subunits. Carbohydrate residues were also attached to Asn 323 and Asn 365 of GBR1b VFT , and to Asn 404 of GBR2 VFT .
All of the antagonist-bound GBR1b VFT :GBR2 VFT structures were solved by molecular replacement using the apo-GBR1b VFT :GBR2 VFT structure as the search model. For each complex, the bound antagonist was modelled into the residual electron density map obtained in the final rounds of refinement. All of the antagonistbound structures contained the GBR1b VFT residues 48-368 and 377-459, the GBR2 VFT residues 53-292, 300-379 and 385-466, and part of the Flag tag at the C termini of both subunits. Carbohydrate residues were also attached to Asn 323 and Asn 365 of GBR1b VFT , and to Asn 404 of GBR2 VFT . Although a racemic mixture of (R)-2-OH-saclofen ANT and (S)-2-OH-saclofen ANT was used for crystallization, only the (S)-2-OH-saclofen ANT enantiomer was bound to GBR1b VFT in the structure. Our observation is consistent with previous findings that the (S)-2-OHsaclofen ANT enantiomer is the active antagonist 54 . Similarly, we found that (R)phaclofen was the active enantiomer, in agreement with previous studies 55 .
The structure of the (R)-baclofen AGO -GBR1b VFT :GBR2 VFT complex was also determined by molecular replacement. The position of GBR2 VFT was found using the GBR2 VFT structure from the apo complex as the search model. The (R)baclofen AGO -bound GBR1b VFT molecule was located using the individual LB1 and LB2 domains of apo-GBR1b VFT as the search probes. A complete model of the (R)-baclofen AGO -GBR1b VFT :GBR2 VFT complex was constructed through iterative rounds of manual building and refinement. The GABA-bound GBR1b VFT : GBR2 VFT structure was solved using the refined (R)-baclofen AGO -GBR1b VFT : GBR2 VFT complex structure as the search model. For each complex, the bound agonist was modelled into the residual electron density map obtained in the final rounds of refinement. The (R)-baclofen AGO -GBR1b VFT :GBR2 VFT complex contained
